Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
15,224
Total Claims
$2.5M
Drug Cost
549
Beneficiaries
$4,502
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+219%
Cost per patient vs peers
$4,502 vs $1,411 avg
+79%
Brand preference vs peers
19.0% vs 10.6% avg
Brand vs Generic
Brand: 2,880 claims · $2.2M
Generic: 12,278 claims · $285K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 275 | $257K |
| Dulaglutide | 98 | $155K |
| Bictegrav/Emtricit/Tenofov Ala | 31 | $138K |
| Empagliflozin | 121 | $127K |
| Semaglutide | 82 | $120K |
| Sitagliptin Phos/Metformin Hcl | 93 | $103K |
| Fluticasone/Umeclidin/Vilanter | 109 | $90K |
| Dapagliflozin Propanediol | 86 | $88K |
| Rivaroxaban | 102 | $84K |
| Mirabegron | 108 | $81K |
| Fluticasone/Vilanterol | 149 | $67K |
| Abacavir/Dolutegravir/Lamivudi | 15 | $57K |
| Sitagliptin Phosphate | 45 | $42K |
| Icosapent Ethyl | 65 | $40K |
| Sacubitril/Valsartan | 33 | $38K |
Prescribing Profile
Patient Profile
73
Avg Age
51%
Female
1.47
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data